Center for Biomedical Innovation (CBI)

At a Glance
  • Status: Active Consortium
  • Year Launched: 2005
  • Initiating Organization: Massachusetts Institute of Technology
  • Initiator Type: Academia
  • No disease focus
  • Location: North America


The Center for Biomedical Innovation (CBI) manages several consortia that address a variety of challenges in the global biomedical industry by developing, testing, and disseminating new knowledge and tools designed for real-world application through the following programs: the Biomanufacturing Program (BioMAN), the Consortium on Adventitious Agents in Biomanufacturing (CAACB), and New Drug Development Paradigms (NEWDIGS).


CBI’s mission is to improve global health by overcoming obstacles to the development and implementation of biomedical innovation. CBI provides a safe and transparent environment for collaborative research among industry, academia, and government, and draws on the expertise of the Massachusetts Institute of Technology’s (MIT) Schools of Engineering, Science, and Management, as well as the Harvard-MIT Division of Health Sciences and Technology (HST).

CBI manages the following consortia:

Biomanufacturing (BioMAN)
BioMAN is a collaborative research and educational program in biotherapeutic manufacturing. Its objective is to develop new knowledge, science, technologies, and strategies that advance the manufacture and global delivery of high-quality biopharmaceuticals. BioMAN activities bring together thought leaders from industry, the government (e.g., U.S. Food and Drug Agency), and academia and involve faculty from across the Schools of Science, Engineering, and Management at MIT.

Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB)
CAACB’s mission is to develop a comprehensive understanding of adventitious agents encountered in biomanufacturing, the sources of such agents, and a systematic, risk-based analysis of the most effective strategies and technologies to prevent contamination.

NEW Drug Development ParaDIGmS (NEWDIGS)  
NEWDIGS focuses on transforming the current global pharmaceutical innovation ecosystem to more reliably and sustainably deliver new, better, and affordable drugs to the right patients faster. System re-engineering projects are designed and executed with input from industry; regulators from the United States, Europe, Singapore, and Canada; payers and health technology assessment officials; and providers, patients, and academic researchers from MIT, Harvard, and other leading academic institutions.

Consortium History

CBI was formed in 2005 as a collaboration among the School of Engineering, the MIT Sloan School of Management, the School of Science, and the Harvard-MIT Division of Health Sciences and Technology (HST) to address the challenges within the pharmaceutical, biotechnology, diagnostics, and medical devices industries with respect to innovation, productivity, and costs and predicting and managing risks.

CBI merged with MIT’s Program on the Pharmaceutical Industry (POPI) in 2008. POPI was founded in 1991 with a major grant from the Alfred P. Sloan Foundation to promote research and educational activities on issues related to competitiveness, performance, and productivity in the pharmaceutical field.


CBI receives funding from the government, industry, and philanthropic organizations. CBI received MIT internal start-up support from the School of Science, the School of Engineering, the MIT Sloan School of Management, the Office of the Provost, and the Office of the Vice President for Research and Associate Provost. The consortium has been successful in obtaining additional grants from MTC/JAII and the Merck Company Foundation to support the development of its business plan and other launch activities and to support research efforts in clinical trials and stratified medicine. In addition, six founding consortium members contribute membership fees to support CBI’s research, educational, and administrative activities.


Accomplishments are listed on the homepage at

Points of Contact

Stacy L. Springs, Ph.D.
Director, BioMAN
Executive Director, Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB)
phone: 617-253-3084

Sponsors & Partners


Alfred P. Sloan Foundation

Alnylam Pharmaceuticals


Aquafine UV

Asahi Kasei Bioprocess

Baxter Pharmaceuticals

Bill and Melinda Gates Foundation

Biogen Idec

Boehringer Ingelheim

Bristol-Myers Squibb

Eli Lilly & Co.

EM.D. Millipore


Georgetown University


Kauffman Foundation

Latham Biopharm Group

Life Technologies

Massachusetts Institute of Technology



Northeastern University


Pall Corporation





Sanofi Pasteur




U.S. Food and Drug Administration

University of Prince Edward Island

Last Updated: 04/14/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.